Cesar Perez, Director of Drug Development at Lake Nona DDU of Florida Cancer Specialists and Research Institute, shared on LinkedIn:
“April is Head and Neck Cancer Awareness Month, a reminder of how much work remains-but also how much progress the field is making.
Across our network at Florida Cancer Specialists and Research Institute and Sarah Cannon Research Institute, advancing research in head and neck cancer remains a central priority. 2025 brought important momentum, including the FDA approval of pembrolizumab for resectable locally advanced HNSCC-the first new approval in this disease in six years.
At the same time, the pipeline is rapidly evolving. Novel antibody–drug conjugates (ADCs) and bispecific antibodies, along with an expanding set of biomarker-driven trials, are beginning to reshape how we think about treatment strategies in this disease.
For clinicians and researchers in head and neck oncology, it feels like the field is entering a new phase-where deeper biology and smarter drug design may finally translate into more durable outcomes for our patients.”
Other articles about Head and Neck Cancer on OncoDaily.